Infusion Center Billing Guide: Drug Administration Codes, Infusion Hierarchy, Drug HCPCS Billing, and Infusion RCM

Drug Administration Hierarchy Rules

The infusion drug administration hierarchy determines which CPT code is the "initial" service and which are add-on services. AMA and CMS guidelines establish the following priority order: Hierarchy order (highest to lowest priority): 1. Chemotherapy agents (most complex, takes priority as "initial" service); 2. Highly complex agents (e.g., biologic agents requiring special handling); 3. Therapeutic, prophylactic, or diagnostic injections; 4. Therapeutic infusions; 5. Hydration; The rule: if a patient receives both a chemotherapy infusion and a hydration infusion in the same encounter, the chemotherapy is the initial service — the hydration is billed as a sequential add-on; even if the hydration was started before the chemotherapy, the chemotherapy is the initial code; one initial code per encounter: only one "initial" infusion code may be billed per encounter; a single encounter may result in multiple add-on codes but only one initial code; the "initial" code includes the first hour of infusion and the preparation and assessment required to set up the infusion; Sequential vs. concurrent: sequential infusion (different drug, same IV line, administered after first drug is complete): add-on codes (96367, +96366, +96368); concurrent infusion (different drug, different IV line, running at the same time as the initial infusion): add-on code +96368; Push vs. infusion: an IV push is a drug administered by direct injection over 15 minutes or less; if the same drug is administered over more than 15 minutes, it becomes an infusion; the threshold of 15 minutes affects code selection; Hydration: hydration (96360, 96361) is at the bottom of the hierarchy and is almost never the initial code when any therapeutic agent is also administered; hydration requires a direct physician order and documented clinical indication — hydration billed without clinical indication (e.g., routine saline flush) does not meet the threshold for hydration CPT billing.

Infusion Administration CPT Codes

The non-chemotherapy therapeutic infusion and injection CPT codes: Therapeutic, prophylactic, diagnostic infusion: 96365 — IV infusion, initial, up to 1 hour (therapeutic, prophylactic, or diagnostic); 96366 — IV infusion, each additional hour (add-on, up to 8 additional hours); 96367 — IV infusion, additional sequential infusion, up to 1 hour (different substance); 96368 — IV infusion, concurrent infusion (different substance/drug); Therapeutic, prophylactic, diagnostic injection: 96372 — Therapeutic, prophylactic, or diagnostic injection (specify substance/drug); subcutaneous or intramuscular; 96374 — Therapeutic, prophylactic, or diagnostic injection, IV push, initial substance; 96375 — IV push, each additional sequential substance; 96376 — IV push, each additional same substance (>30 minutes after initial); Hydration: 96360 — IV hydration infusion, initial, 31 minutes to 1 hour; 96361 — IV hydration, each additional hour (add-on); hydration must be ≥31 minutes — routine IV flushes are not separately billable; Time-based billing for infusions: infusion duration must be documented; the clock starts when the drug begins infusing (not when the IV is started); 30-minute rounding rules: to bill 96366 (additional hour), the total infusion time must be at least 30 minutes beyond the first hour (i.e., ≥1 hour 31 minutes total to bill one additional hour); to bill a second additional hour, total time must be ≥2 hours 31 minutes; Separate reporting for each drug: each drug infused requires: the administration code (initial, sequential, or concurrent); the drug HCPCS code (for the specific drug product); both components must appear on the claim; Do not bundle: the administration code and the drug code are separate line items — billing only the drug HCPCS code without the administration code misses the administration reimbursement; billing only the administration code without the drug HCPCS code misses the drug reimbursement.

Chemotherapy Administration Codes

Chemotherapy administration codes are separate from therapeutic infusion codes and reflect the additional complexity and safety requirements of cytotoxic drug administration: Chemotherapy infusion: 96413 — Chemotherapy administration, IV infusion, initial, up to 1 hour; 96415 — Chemotherapy, each additional hour (add-on); 96417 — Chemotherapy, each additional sequential infusion, up to 1 hour (different drug); Chemotherapy injection: 96401 — Chemotherapy, non-hormonal anti-neoplastic agent, subcutaneous or intramuscular; 96402 — Chemotherapy, hormonal anti-neoplastic agent, subcutaneous or intramuscular; Chemotherapy push: 96409 — Chemotherapy, IV push, single or initial substance; 96411 — Chemotherapy, IV push, each additional sequential substance; Highly complex biological agent infusion: 96365 is NOT appropriate for biologic agents in an oncology setting where the drug meets criteria for higher-complexity coding; some payers require 96413 for biologic agents that are classified as chemotherapy agents; verify payer policy; Physician supervision requirements: CMS requires direct physician supervision for chemotherapy administration in the office setting; for incident-to billing, the administering physician must be physically present in the office suite during chemotherapy infusion; the physician does not need to be in the room, but must be in the office and immediately available; REMS programs: several chemotherapy agents are subject to FDA Risk Evaluation and Mitigation Strategies (REMS) that require: prescriber certification; pharmacy certification; patient enrollment; documentation of REMS compliance in the chart; REMS-required drugs include: bortezomib (Velcade), thalidomide (Thalomid), lenalidomide (Revlimid), carfilzomib (Kyprolis), and others; claims for REMS drugs without documented REMS compliance are a compliance risk; E&M with chemotherapy: an E&M service (99202-99215) may be billed in addition to chemotherapy administration if the E&M is separately documented and medically necessary beyond the chemotherapy administration assessment; the E&M must document a separately identifiable service (e.g., evaluation of a new symptom, adjustment of supportive care medications).

Drug HCPCS Billing and NDC Numbers

Every drug administered in the infusion center must be billed using the applicable HCPCS Level II code plus the National Drug Code (NDC) number: Drug HCPCS codes: most drugs have specific HCPCS J-codes (e.g., J0881 — darbepoetin alfa injection, 1 mcg; J1745 — infliximab injection, 10 mg; J9035 — bevacizumab injection, 10 mg); some drugs are billed using non-specific codes (J3490 — unclassified drugs, J3590 — unclassified biologics) when no specific HCPCS code has been assigned; NDC billing requirement: Medicare Part B requires that the NDC number be submitted with each drug claim; the NDC identifies the specific drug product: manufacturer, drug name, strength, and package size; NDC format on claims: the 11-digit NDC must be submitted in the qualifier field: qualifier N4 followed by the 11-digit NDC in 5-4-2 format; billing the wrong NDC (drug was NDC-xxxx but a different NDC was submitted) creates a pricing discrepancy; Units billing: drug HCPCS codes are billed in the units specified by the code description; J9035 is per 10 mg of bevacizumab — if 400 mg was administered, bill 40 units of J9035; the number of units must match the drug quantity documented in the medication administration record; drug wastage: when a drug vial is opened and only a portion is used, the remainder (wastage) may be billable under some circumstances; for single-dose vials, Medicare allows billing for the full vial when medically necessary to open it, even if only a portion was used — Modifier JW (drug amount discarded/not administered to any patient) must be appended to the claim for the wasted portion; multi-dose vials: wastage from multi-dose vials (where multiple patients can be served from one vial) is not separately billable; Average Sales Price (ASP): Medicare Part B pays for most Part B drugs at ASP + 6%; the ASP for each drug is updated quarterly by CMS; when billing 340B-acquired drugs, Modifier JG (drug or biological acquired with 340B drug pricing program discount) is required on the drug claim.

Infusion Center Revenue Cycle

Infusion centers have a distinct revenue cycle driven by the combination of high-cost drugs and complex administration billing: Prior authorization for infusion drugs: virtually every specialty drug administered in the infusion center requires prior authorization; PA must specify: drug name and HCPCS code; diagnosis code (must match the FDA-approved indication or documented off-label use with clinical support); dose and frequency; prescribing physician; PA denials for infusion drugs: appeals should include clinical documentation supporting the indication; step therapy requirements (payers requiring formulary agents before specialty agents) must be documented as failed or inappropriate; Site-of-care management: payers and employers are increasingly directing infusion patients from hospital-based infusion centers (HOPD) to physician office-based infusion centers or home infusion because of cost differences; HOPD infusion reimbursement is typically 2–5× higher than the same service in a physician office; this creates a significant site-of-care arbitrage issue that affects infusion center volumes; Specialty pharmacy and buy-and-bill: infusion centers using buy-and-bill (the center purchases the drug and bills the payer) must manage: drug acquisition cost (invoice cost vs. ASP reimbursement); inventory management and drug storage; Medicare ASP + 6% vs. commercial payer contracted rates for drugs; 340B eligibility and Modifier JG; some centers use specialty pharmacy arrangements where the payer pays the pharmacy directly for the drug and the center bills only for the administration — eliminating buy-and-bill margin but also eliminating drug acquisition risk; Financial counseling for infusion patients: specialty drug patient cost-sharing can be thousands of dollars per treatment; patient assistance programs (manufacturer copay cards, foundation assistance) must be researched before treatment begins; copay assistance coordination is an essential infusion center RCM function.